Inhibition of CXCL8 activity might represent a relevant therapeutic target to prevent injury
occurring after pancreatic islet transplantation. Reparixin is a novel and specific inhibitor
of CXCL8. This study is designed to explore the efficacy of reparixin in preventing graft
dysfunction after islet transplantation in type 1 diabetes patients (T1D).